Kymera Therapeutics (KYMR) Citi Annual Global Healthcare Conference 2025 summary

Company evolution and strategic focus

• Approaching 10-year anniversary, with significant evolution in capabilities and pipeline, now focused on immunology and targeted protein degradation.

• Pipeline includes two wholly owned programs: STAT6 (data imminent) and IRF5 (clinic entry next year), plus partnered programs with Sanofi (IRAK4, clinic in 2026) and Gilead (CDK2, updates expected next year).

STAT6 (621) program and clinical development

• STAT6 program aims for biologic-like efficacy and safety in atopic dermatitis (AD) with oral administration, targeting a large, underserved market.

• Phase IB data readout expected soon; objectives include confirming dose, translating safety/PK/PD, and demonstrating Dupi-like biomarker effects at 28 days.

• Phase II AD study has begun, with Phase IIB asthma study planned for early next year; company believes it leads competitors by at least a year.

• Differentiation from Dupi centers on oral delivery, potential for broader access, and comparable efficacy/safety, especially in pediatric populations.

Biomarker strategy and patient population

• Focus on Th2 biomarkers (TARC, Eotaxin) in blood and skin to benchmark against Dupi; skin biopsies and transcriptome analysis included.

• Initial focus is on Dupi-naive patients due to low Dupi penetration; prior Dupi responders allowed with washout.

• Large AD population remains underserved due to biologic limitations, cost, and access issues.